Sobi Shares Rally After Strong Q2 Earnings and Upgraded Full-Year Guidance

Shares of Swedish Orphan Biovitrum AB (Sobi) rallied more than 4% on Tuesday after the Stockholm-listed biopharmaceutical firm reported strong second-quarter results and raised its financial guidance for the full year.

The company's stock rose 4.3% to SEK 475.6, approaching its 52-week high, as investors reacted positively to the improved outlook and accelerating growth.

Strong Q2 Results Drive Outlook Upgrade

Sobi announced that its total revenue for the second quarter grew 29% at constant exchange rates (CER) to SEK 7.84 billion, up from SEK 6.17 billion in the same period a year earlier.

Based on this performance, the company upgraded its full-year forecast. Sobi now expects revenue growth in the mid-to-high-teens percentage range at CER, an increase from its prior guidance of low double-digit growth. The company also lifted its adjusted EBITA margin guidance to the mid-to-high-30s percentage range, up from a previous forecast of the mid-30s.

Broad-Based Growth Across Key Franchises

Ad

The revenue outperformance was driven by strong results across Sobi's two main business segments. The company reported robust sales growth for its key treatments in Haematology and Immunology.

• Haematology: Revenue increased by 27% at CER to SEK 5.73 billion, led by strong sales of Altuvoct, which more than doubled to SEK 1.55 billion, and Doptelet, which grew to SEK 1.63 billion.
• Immunology: Revenue rose by 37% at CER to SEK 1.71 billion, primarily driven by sales of Gamifant and Kineret.

Market Context

Tuesday's stock price increase pushed Sobi's shares toward their 52-week peak of SEK 487, marking a significant advance from the 52-week low of SEK 261.2. The rally reflects renewed investor confidence in the company's growth trajectory for its rare-disease portfolio.

The positive results align with a broadly supportive analyst consensus. According to the source, 10 analysts recommend buying the stock, with none suggesting a sell.